Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GEM 91 25 nucleotide antisense molecule: HYBN will begin a Phase II trial

Hybridon Inc. (HYBN), Cambridge, Mass.
Product: GEM

Read the full 75 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE